Gibraltar Capital Management Inc. bought a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,450 shares of the company’s stock, valued at approximately $212,000.
Several other hedge funds also recently bought and sold shares of the company. Arjuna Capital lifted its position in Johnson & Johnson by 20.1% during the 2nd quarter. Arjuna Capital now owns 23,969 shares of the company’s stock worth $3,338,000 after buying an additional 4,017 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 261.5% during the 2nd quarter. Victory Capital Management Inc. now owns 525,331 shares of the company’s stock worth $73,168,000 after buying an additional 379,992 shares during the last quarter. Centaurus Financial Inc. grew its holdings in shares of Johnson & Johnson by 612.1% in the 2nd quarter. Centaurus Financial Inc. now owns 4,807 shares of the company’s stock valued at $670,000 after acquiring an additional 4,132 shares in the last quarter. OneAscent Financial Services LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $214,000. Finally, Worldquant Millennium Advisors LLC grew its holdings in shares of Johnson & Johnson by 19.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 177,065 shares of the company’s stock valued at $24,662,000 after acquiring an additional 28,654 shares in the last quarter. Institutional investors own 67.36% of the company’s stock.
In other Johnson & Johnson news, Director Hubert Joly bought 5,000 shares of Johnson & Johnson stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $141.28 per share, for a total transaction of $706,400.00. Following the purchase, the director now owns 5,000 shares of the company’s stock, valued at approximately $706,400. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 2,017 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $141.07, for a total value of $284,538.19. Following the transaction, the executive vice president now owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.
Shares of JNJ stock opened at $149.27 on Wednesday. Johnson & Johnson has a 52-week low of $125.00 and a 52-week high of $150.17. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The stock has a market cap of $392.60 billion, a price-to-earnings ratio of 23.32, a PEG ratio of 2.40 and a beta of 0.71. The firm’s 50-day moving average is $144.44 and its 200-day moving average is $135.05.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 25th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Several research firms recently issued reports on JNJ. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price on the stock in a report on Wednesday, December 18th. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Raymond James dropped their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research note on Friday, October 11th. Finally, Cantor Fitzgerald assumed coverage on Johnson & Johnson in a report on Wednesday, November 27th. They issued an “overweight” rating and a $160.00 price objective for the company. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $159.33.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: S&P 500 Index
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.